Asacol 1.6 g uses the new technology concept OPTICORE™

Download PDF Czech version

Authors: Lukáš M.
Authors‘ workplace: Klinické a výzkumné centrum pro idiopatické střevní záněty ISCARE I. V. F. a. s. a 1. LF UK, Praha
Published in: Gastroent Hepatol 2019; 73(5): 455-456
Category:
doi: https://doi.org/10.14735/amgh2019455

Sources

1. Lukáš M. Konvenční medikamentózní terapie. In: Lukas M (ed). Pokroky v diagnostice a léčbě idiopatických střevních zánětů. Galen 2019. In press.

2. Varum F, Freire AC, Bravo R et al. OPTICORE™: Accelerating drug release in the ileo-colonic region of the gastrointestinal tract. Poster AAPS National Biotechnology Conference 2016.

3. Varum F, Buser T, Good S et al. OPTICORE™: in vivo accurate targeting of the ileo-colonic region of the gastrointestinal tract. ResearchGate 2016. [online]. Available from: https: //www.researchgate.net/publication/312154095_OPTICORE_In_vivo_accurate_targeting_of_the_ileo-colonic_region_of_the_gastrointestinal_tract.

4. D’Haens G, Sandborn WJ, Zou G et al. Randomized non-inferiority trial: 1 600 mg versus 400 mg tablets of mesalazine for the treatment of mild to moderate ulcerative colitis. Aliment Pharmacol Ther 2017; 46 (3) : 292– 302. doi: 10.1111/ apt.14164.